G1 Therapeutics (GTHX) Appoints Norman E. Sharpless to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
July 25, 2022 6:30 AM EDTRESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. Ned Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against cancer, including serving as one of the scientific founders of G1 in 2008. He is an accomplished oncologist and seasoned public servant who has treated cancer patients, investigated the biologic basis of cancer, and has led academic institutions and government agencies, including most recently serving as... More
